Phospho-TP53 (S376) Antibody

What is the significance of p53 phosphorylation at serine 376?

Phosphorylation at serine 376 plays a pivotal role in modulating p53's activity. Loss of phosphorylation at S376 leads to the binding of p53 to 14-3-3 proteins, which significantly increases p53's DNA-binding ability and influences subsequent phosphorylation at the adjacent S378 residue . This phosphorylation event represents one of several regulatory mechanisms by which p53's transcriptional activity is fine-tuned in response to cellular stress signals. The phosphorylation status at S376 can therefore serve as an important biomarker for assessing p53 activation status in various experimental contexts.

How does phosphorylation at S376 differ from other p53 phosphorylation sites in terms of function?

While several p53 phosphorylation sites (such as S15 and S20) primarily regulate p53's interaction with MDM2 and subsequent stability, S376 phosphorylation distinctly affects p53's DNA-binding properties. DNA damage induces phosphorylation at sites like S15 and S20, which reduces interaction between p53 and its negative regulator MDM2, thus preventing ubiquitination and proteasomal degradation . In contrast, S376 modification directly modulates DNA-binding functionality by facilitating interaction with 14-3-3 proteins when dephosphorylated . This site-specific regulation represents part of a complex regulatory network that allows for nuanced control of p53's various functions.

What are the key technical specifications of commercially available Phospho-TP53 (S376) antibodies?

Most commercially available Phospho-TP53 (S376) antibodies are rabbit monoclonal or polyclonal antibodies that specifically recognize p53 protein phosphorylated at serine 376. For example, the Anti-p53 (phospho S376) antibody [EPR17730] is a rabbit recombinant monoclonal antibody suitable for Western blotting and dot blot applications . It typically has a recommended dilution of 1/1000 for Western blot applications and has demonstrated specificity in discriminating between phosphorylated and non-phosphorylated forms of the epitope . These antibodies generally detect a band of approximately 53 kDa, which corresponds to the phosphorylated form of p53.

What are the optimal experimental conditions for Western blotting with Phospho-TP53 (S376) antibody?

For optimal Western blotting results with Phospho-TP53 (S376) antibody, researchers should consider the following protocol:

• Sample preparation: Treat cells with phosphatase inhibitors (such as 200nM Calyculin A and 1μM Okadaic Acid for 60 minutes) to preserve phosphorylation .

• Blocking: Use 5% non-fat dry milk (NFDM) in TBST as blocking buffer .

• Primary antibody: Dilute the Anti-p53 (phospho S376) antibody to 1/1000 in blocking buffer and incubate overnight at 4°C .

• Secondary antibody: Use anti-rabbit IgG HRP-conjugated antibody at 1/1000 dilution .

• Controls: Include both treated and untreated samples to demonstrate specificity for the phosphorylated form .

• Loading control: Include a total p53 antibody on stripped membranes to normalize for total p53 levels.

The expected band size is 53 kDa, though the theoretical molecular weight of p53 is 43 kDa, with the difference attributable to post-translational modifications .

How can I validate the specificity of Phospho-TP53 (S376) antibody in my experimental system?

Validating antibody specificity for phospho-epitopes requires multiple approaches:

• Phosphatase treatment: Treat a duplicate sample with lambda phosphatase prior to immunoblotting. Loss of signal confirms phospho-specificity, as demonstrated with other phospho-p53 antibodies .

• Peptide competition: Compare signal between phospho-peptide and non-phospho-peptide dot blots. The antibody should only recognize the phosphorylated form .

• Cellular treatments: Compare cells treated with phosphatase inhibitors versus untreated cells. Enhanced signal in treated samples supports phospho-specificity .

• Knockout/knockdown controls: Test the antibody in p53-null or p53-knockdown cells to confirm absence of non-specific binding.

• Site-directed mutagenesis: Test the antibody against p53 with an S376A mutation, which should eliminate the signal if the antibody is truly specific.

What cellular treatments effectively induce or alter p53 phosphorylation at S376?

Several treatments can modulate p53 phosphorylation at S376:

• Phosphatase inhibitors: Treatment with 200nM Calyculin A and 1μM Okadaic Acid for 60 minutes significantly enhances S376 phosphorylation detection in HEK-293 cells .

• DNA damage agents: Compounds such as camptothecin (1μM for 5 hours) can affect the phosphorylation pattern of p53, including S376, as part of the DNA damage response .

• Serine/threonine kinase activators: Since phosphorylation at S376 is mediated by specific kinases, activators of these pathways can enhance phosphorylation.

• Cell cycle synchronization: The phosphorylation status of p53 at S376 may vary throughout the cell cycle, so synchronized cell populations might show different levels of phosphorylation.

What are common issues when detecting phospho-p53 (S376) and how can they be resolved?

How should I interpret discrepancies between total p53 and phospho-S376 p53 signals?

Discrepancies between total p53 and phospho-S376 signals require careful interpretation:

• Signal in phospho-S376 without corresponding total p53: This likely indicates non-specific binding or cross-reactivity of the phospho-antibody. Validate with additional controls or alternative antibodies.

• Strong total p53 signal with weak phospho-S376 signal: This suggests that only a fraction of the total p53 pool is phosphorylated at S376. This is normal and reflects the dynamic nature of post-translational modifications. Consider whether your experimental conditions should activate this specific phosphorylation.

• Variations across cell lines: Different cell lines may exhibit different basal levels of S376 phosphorylation due to variations in kinase/phosphatase activity. Always include appropriate positive controls specific to your cell system.

• Temporal discrepancies: Phosphorylation events are often transient and may occur before changes in total protein levels. Consider performing time-course experiments to capture the dynamics of phosphorylation events.

How can I determine the relative abundance of phosphorylated versus non-phosphorylated p53 at S376?

To determine the relative abundance of phosphorylated versus non-phosphorylated p53 at S376:

• Sequential immunoprecipitation: First immunoprecipitate total p53, then perform Western blot with phospho-S376 antibody. The ratio provides an estimate of phosphorylation stoichiometry.

• Phosphatase treatment: Divide your sample into two aliquots, treat one with lambda phosphatase, then detect with total p53 antibody. The mobility shift can provide information about the proportion of phosphorylated protein.

• Phos-tag™ SDS-PAGE: This technique retards the migration of phosphorylated proteins, allowing separation of phosphorylated and non-phosphorylated forms.

• Mass spectrometry: For precise quantification, mass spectrometry can provide exact stoichiometry of modification sites when combined with isotope labeling techniques.

How can I use Phospho-TP53 (S376) antibody in combination with other phospho-specific antibodies to profile p53 activation states?

Profiling p53 activation states using multiple phospho-specific antibodies provides deeper insight into pathway activation:

• Multiplexed Western blotting: Use antibodies with distinct species origins or targeting different-sized proteins to probe a single membrane for multiple phosphorylation sites.

• Phosphorylation pattern analysis: Compare phosphorylation at S15, S20, S37, S46, and S376 simultaneously using a phospho-p53 antibody sampler kit . Different stress stimuli induce distinct phosphorylation patterns – for example, DNA damage strongly induces S15 and S20 phosphorylation to prevent MDM2 binding, while S376 dephosphorylation enhances DNA binding .

• Sequential immunoprecipitation: Immunoprecipitate with one phospho-specific antibody, then probe the immunoprecipitate with another to identify subpopulations with multiple modifications.

• Flow cytometry: For single-cell analysis, combine phospho-p53 antibodies with cell cycle markers to correlate phosphorylation status with cell cycle position.

• ChIP-seq following immunoprecipitation: Use phospho-S376 antibody for chromatin immunoprecipitation followed by sequencing to identify genome-wide binding sites specific to this phosphorylation state.

What insights can be gained from studying the relationship between p53 S376 phosphorylation and 14-3-3 protein binding?

The relationship between S376 phosphorylation and 14-3-3 protein binding offers significant research insights:

• Dephosphorylation at S376 creates a binding site for 14-3-3 proteins, enhancing p53's DNA-binding ability . This represents a key regulatory switch in p53 function.

• Co-immunoprecipitation experiments using phospho-S376 antibody can reveal whether 14-3-3 binding is mutually exclusive with S376 phosphorylation, confirming the mechanistic model.

• The presence of S376 phosphorylation versus 14-3-3 binding can be used to distinguish different p53 activation states in response to various cellular stresses.

• Mutation studies (S376A or S376D/E) can help establish the functional consequences of this phosphorylation site for p53-dependent transcriptional programs and cellular outcomes.

• Investigation of kinases and phosphatases regulating S376 phosphorylation status can identify additional regulatory layers in the p53 pathway.

How does the phosphorylation status at S376 correlate with other post-translational modifications of p53?

The interrelationship between S376 phosphorylation and other p53 modifications reveals complex regulatory networks:

• Hierarchical modifications: Phosphorylation at S376 may influence or be influenced by modifications at neighboring sites such as S378, creating a phosphorylation "code" .

• Cross-talk with acetylation: The C-terminal domain of p53 contains both phosphorylation and acetylation sites; investigating whether S376 phosphorylation affects C-terminal acetylation by p300/CBP could reveal important regulatory mechanisms .

• Ubiquitination interference: The relationship between S376 phosphorylation and MDM2-mediated ubiquitination remains to be fully characterized, though other phosphorylation events (S15, S20) are known to inhibit MDM2 binding .

• Modification patterns in tumors: S392 phosphorylation is increased in human tumors ; studying the correlation between S376 and S392 phosphorylation status could reveal tumor-specific p53 modification signatures.

How does Phospho-TP53 (S376) antibody compare with other conformation-specific p53 antibodies?

Phospho-TP53 (S376) antibody differs from conformation-specific p53 antibodies in several important ways:

What are the methodological differences in using antibodies targeting different phosphorylated residues of p53?

Different phospho-specific p53 antibodies require distinct methodological considerations:

• Induction conditions: Different phosphorylation sites respond optimally to different treatments. While S376 phosphorylation is readily detected after phosphatase inhibitor treatment , S37 phosphorylation responds strongly to camptothecin treatment , and S15/S20 phosphorylation is induced by DNA damage .

• Temporal dynamics: Phosphorylation sites show different kinetics—some are rapidly modified and others show delayed responses. Time-course experiments are essential for capturing the appropriate window for each modification.

• Background issues: N-terminal phospho-antibodies (S15, S20, S37) typically show cleaner results in Western blotting compared to C-terminal antibodies, which may require more stringent blocking conditions .

• Functional validation: While detecting phosphorylation is important, functional validation differs by site. For S376, functional consequences include 14-3-3 binding and enhanced DNA binding , while S15/S20 phosphorylation affects MDM2 interaction .

How has the development of phospho-specific p53 antibodies contributed to our understanding of p53 biology?

The development of phospho-specific p53 antibodies has revolutionized our understanding of p53 biology in several key ways:

• Pathway delineation: These antibodies have enabled researchers to map the complex signaling networks that regulate p53, identifying key kinases like ATM, ATR, DNA-PK (for S15/S37), Chk1/Chk2 (for S20), and CK1δ/ε (for S6/S9) .

• Stress-specific responses: Different cellular stresses induce distinct phosphorylation patterns, revealed through the use of site-specific antibodies. This has allowed researchers to understand how p53 differentially responds to various types of damage.

• Tumor-specific modifications: Identification of phosphorylation sites like S392 that show increased modification in human tumors has provided important biomarkers and potential therapeutic targets .

• Mechanistic insights: The discovery that antibodies like PAb421, which bind the C-terminal domain of p53, can enhance p53's DNA-binding ability revolutionized our understanding of p53 regulation, revealing the negative regulatory role of the C-terminal domain .

• Structure-function relationships: Phospho-specific antibodies have helped establish the relationship between specific modifications and functional outcomes, such as the link between S376 dephosphorylation, 14-3-3 binding, and enhanced DNA binding .